IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10155764 B1

PDFFull Text
Date of Patent:
Dec. 18, 2018

Filed:

Mar. 03, 2017

Therapeutic compounds and uses thereof

Applicants:

Genentech, Inc., South San Francisco, CA (US);

Constellation Pharmaceuticals, Inc., Cambridge, MA (US);

Inventors:

Brian K. Albrecht, Cambridge, MA (US);

Alexandre Cote, Cambridge, MA (US);

Terry Crawford, South San Francisco, CA (US);

Martin Duplessis, Cambridge, MA (US);

Andrew Charles Good, Cambridge, MA (US);

Yves LeBlanc, Cambridge, MA (US);

Steven Magnuson, South San Francisco, CA (US);

Christopher G. Nasveschuk, Cambridge, MA (US);

Richard Pastor, South San Francisco, CA (US);

Anthony F. Romero, South San Francisco, CA (US);

Alexander M. Taylor, Cambridge, MA (US);

Assignees:

GENENTECH, INC, South San Francisco, CA (US);

CONSTELLATION PHARMACEUTICALS, INC., Cambridge, MA (US);

Attorney:

Viksnins Harris Padys Malen LLP

Primary Examiner:

Paul V Ward

Int. Cl.
CPC ...
C07D 487/04 (2006.01); C07D 403/12 (2006.01); C07D 401/12 (2006.01); C07D 237/32 (2006.01); C07D 471/04 (2006.01); A61K 31/502 (2006.01); A61K 31/5025 (2006.01); A61K 31/5377 (2006.01); A61K 31/55 (2006.01); C07D 237/34 (2006.01); C07D 405/12 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); A61K 31/502 (2013.01); A61K 31/5025 (2013.01); A61K 31/5377 (2013.01); A61K 31/55 (2013.01); C07D 237/32 (2013.01); C07D 237/34 (2013.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 471/04 (2013.01);
Abstract

The present invention relates to methods for treating PCAF and GCN5 mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein ring A, R, R, R, R, and each Rhave any of the values defined in the specification. Also included are novel compounds of Formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.

Find Patent Forward Citations

Loading…